

Die Rolle der PSMA-PET/CT im Rahmen der Prostatastanzbiopsie

Philipp Krausewitz

Literatur

1. Hofman MS et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet* 2020; 395: 1208–16
2. Sonni I et al. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging study with histopathology gold-standard. *Journal of Clinical Oncology* 2021; 39: 193
3. Kesch C et al. Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer. *Sci Rep* 2018; 8: 16708
4. Kalapara AA et al. Detection and localisation of primary prostate cancer using (68)gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. *BJU Int* 2020; 126: 83–90
5. Kasperzyk JL et al. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2013; 22: 2354–63
6. Chang SS. Overview of prostate-specific membrane antigen. *Rev Urol* 2004; 6(10): 13-8
7. Amiel T et al. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. *J Urol* 2021; 205: 1663–70
8. Franklin A et al. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. *BJU Int* 2021; 127: 71–9

9. Simopoulos DN et al. Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance. *Urol Case Rep* 2017; 14: 11–4
10. Lopci E et al. (68)Ga Prostate-specific Membrane Antigen PET/CT for Primary Diagnosis of Prostate Cancer: Complementary or Alternative to Multiparametric MR Imaging. *Radiology* 2018; 287: 725–6
11. Lopci E et al. Prospective Evaluation of (68)Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. *Eur Urol Focus* 2021; 7: 764–71
12. Li Y et al. Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy. *Sci Rep* 2020; 10: 10963
13. Zhang L-L et al. (68)Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. *Eur J Nucl Med Mol Imaging* 2021; 48: 483–92
14. Kawada T et al. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol* 2022; 5: 390–400
15. Zettinig O et al. Multimodal image-guided prostate fusion biopsy based on automatic deformable registration. *Int J Comput Assist Radiol Surg* 2015; 10: 1997–2007
16. Emmett L et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. *Eur Urol* 2021; 80: 682–9
17. Krausewitz P et al. DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial. *Trials* 2023; 24: 167
18. Valerio M et al. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. *Eur Urol* 2015; 68: 8–19
19. Mazzone E et al. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol* 2021; 4: 697–713

20. Chen M et al. Combination of (68)Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis. *J Nucl Med* 2019; 60: 944–9
21. Hicks RM et al. Diagnostic Accuracy of (68)Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. *Radiology* 2018; 289: 730–7
22. Evangelista L et al. PET/MRI in prostate cancer: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging* 2021; 48: 859–73
23. Scheltema MJ et al. Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. *BJU Int* 2019; 124(1): 42–9
24. Margel D et al. Diagnostic Performance of (68)Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer. *Radiology* 2021; 301: 379–86
25. Ferraro DA et al. Impact of (68)Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. *Eur J Nucl Med Mol Imaging* 2020; 47: 652–64
26. Cytawa W et al. Diverse PSMA expression in primary prostate cancer: reason for negative (68)Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens. *Eur J Nucl Med Mol Imaging* 2022; 49: 3938–49